Tony Wyss-Coray, | 2020

A Transcriptional Rejuvenation Signature for Alzheimer’s Disease

Qisheng Zhang, John Sondek, Kenneth Pearce, | 2020

Small Molecule Activators of PLC-gamma-2 as Novel Therapeutics for Alzheimer’s Disease

Deepak Kumar Vijaya Kumar, Nanda Kumar Navalpur Shanmugam, Rudy Tanzi, William Eimer, | 2020

Characterizing Gut Microbiome Synergy With Emphasis on Mycobiome and Its Impact on Alzheimer’s Disease (AD) Pathology in AD Mouse Models

Steven L. Wagner, | 2020

Comprehensive Analyses of Chronic Efficacy Studies with GSM 776890 for Submission of the Pre-IND Brochure to the FDA Prior to Pre-IND Meeting and IND Filing for the SAD/MAD Phase I Safety/Toxicity and Ultimately for Phase II and Phase III Efficacy Clinical Trials to Support the NDA

Nanda Kumar Navalpur Shanmugam, Deepak Kumar Vijaya Kumar, Rudy Tanzi, William Eimer, | 2020

Microbes and Alzheimer’s Disease: Metagenomics on Saliva, Cerebrospinal Fluid, Blood and Brain

Ali Ezzati, Richard Lipton, | 2020

Improving Alzheimer’s Disease Clinical Trials’ Design by Machine Learning Models

William Eimer, Deepak Kumar Vijaya Kumar, Rudy Tanzi, | 2019

Tau and Amyloid Beta are Innate Immune Antimicrobial Peptides in the Brain

Rudy Tanzi, | 2005

Alzheimer’s Genome Project™